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ABSTRACT
Objective: The purpose of this research was to develop and formulate proniosomal gel drug delivery system of ethinylestradiol and levonorgestrel for 
antifertility treatment that is capable of efficiently delivering entrapped drug over an extended period of time.
Methods: Ethinylestradiol and levonorgestrel are encapsulated in various formulations of proniosomal gel composed of various ratios of span 
surfactant, cholesterol, soya lecithin, and alcohol as aqueous phase prepared by coacervation-phase separation method. The prepared formulations 
characterized for drug encapsulation efficiency, size distribution, in vitro release studies, and vesicular stability at different storage conditions were 
carried. Stability studies for proniosomal gel were carried out for a few weeks. Morphological size and shape of the vesicles are characterized using 
optical microscopy and scanning electron microscopy (SEM). Stability studies for proniosomal gel were carried out for 3 months.
Results: Morphological size and shape of the vesicles are characterized using optical microscopy and SEM, particles are found to be spherical, size of 
the particles is in the range of 46.4–80.6 nm, and permeation studies showed good control release for prolonged period of time. The encapsulation 
efficiency of proniosomal gel formulations is in the range of 74–80% and in vitro permeation studies proved that good amount of drug is permeated 
and has reasonably good stability characteristics as well.
Conclusions: The results suggest that proniosomal gel formulations of ethinylestradiol and levonorgestrel may be used for transdermal delivery for 
antifertility treatment. The dried proniosomal formulation could act as a promising alternative to niosomes.
Keywords: Estradiol, Formulation development, Levonorgestrel, Transdermal matrix patches.
INTRODUCTION
Contraception was used by women in the form of pills, intrauterine 
device, Norplant, foaming tablets, nasal spray, and condoms, and coitus 
interruptus was used by men. Limitation of contraceptive is mainly 
their side effect and failure rate related to the consumer compliance. 
Vesicular structures such as niosomes, ethosomes, transfersomes, and 
liposomes are favorable systems to go this permeation barrier. But 
their main disadvantage is their instability, which can be overcome by 
the usage of provesicular tactics like proniosomes, proliposomes and 
provesicular, protransfersomes procedures which can further enhance 
the efficacy of vesicles. These approaches may triumph over pores 
and skin barrier properties and beautify percutaneous absorption. In 
these systems, hydrophilic and lipophilic pill drugs may be integrated. 
The proniosomes are dry formulation which is water-soluble carrier, 
covered with surfactant, it is dehydrated to make  niosomal dispersion 
and can be rehydrated by agitating in hot aqueous media within few 
minutes. The ensuing niosomes are uniform in size. Proniosomes 
are the latest development in novel drug delivery device. These are 
most advanced drug provider in a vesicular system which overcomes 
demerits of liposomes and niosomes [1,2].
Ethinylestradiol is regularly utilized in female hypogonadism, and 
treatment of prostate cancer, as the estrogenic component of combined 
oral contraceptive and it is frequently used in menopausal symptoms, 
as the estrogen for menstrual disorders and estrogenic component for 
combined oral contraceptive and with the daily dose of ethinylestradiol 
is 20–50 µg [3].
Levonorgestrel is a powerful progestogen and has been broadly 
prescribed as a contraceptive steroid for female fertility regulation. 
It has been found that, if progestin alone is used as a contraceptive, 
it produced episodes of irregular and unpredictable spotting and 
numerous untoward effects. Their side effects were the main reasons 
why women discontinued its use. The daily day dose of levonorgestrel 
is 30–37 µg in step with day. Alone use of progestin is less efficacious 
than combination oral contraceptives.
Therefore, the study indicates that the combined mixture of ethinylestradiol 
and levonorgestrel turned into a powerful contraceptive formulation. 
Therefore, the objective of the study is to formulate the proniosomes of 
levonorgestrel and ethinyl estradiol for antifertility treatment [4].
MATERIALS AND METHODS
Materials
Levonorgestrel and ethinylestradiol were received as a gift sample 
from Cochin and Ontop Pharmaceuticals Ltd., Bengaluru. Cholesterol, 
soya lecithin, Span 20, and alcohol were procured from S. D. Fine 
Chemical Ltd., Mumbai, and Central Drug Store. All chemicals were used 
as received without any further purification.
Method of preparation
Proniosomal gel was prepared by a method known as coacervation-
phase separation method. Precise amounts of non-ionic surfactant, 
cholesterol, lecithin, and drug (10 ml) were weighed and taken in a 
clean and dry wide-mouthed glass flask of 5.0 ml capacity, and alcohol 
was further added to it. All the ingredients such as cholesterol and 
lecithin were mixed well with a glass rod; the open end of the glass 
bottle was covered with a lid to prevent the loss of solvent from it 
and warmed over a water bath at 60–70°C for about 5 min until the 
surfactant mixture was dissolved completely. Then, the aqueous phase 
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(0.1% glycerol solution) was added and warmed on a water bath until a 
clear solution was formed which was converted into proniosomal gel on 
cooling. The gel so obtained was preserved in the same glass bottle in 
dark conditions for characterization [5]. Compositions of proniosomal 
gel formulations are given in Table 1.
Characterization of proniosomal gel
Physical appearance
The prepared gel was viewed by the naked eye to characterize color 
and physical state of gel. Proniosomal gel was also viewed by optical 
microscope, to observe the characteristics of gel by spreading 
proniosomal gel on a slide which was hydrated with phosphate saline 
(pH 7.4) to produce niosome. A drop of niosomal suspension was 
placed on a slide  and after placing coverslip,  is further observed under 
microscope` [6].
Vesicle size analysis and size distribution
Hydrated proniosomal gel as niosomal suspension was evaluated 
for niosomal size. The dispersion was observed under optical 
microscope at ×100 magnification. The size of 200 vesicles was 
measured using a calibrated ocular and stage micrometer fitted in the 
optical microscope [6].
Viscosity study
About 1 g of proniosomal gel was taken in a tube and 10 ml of distilled 
water was added on it and then stored for 7 h. Results showed that the 
proniosomal gel mixture obtains a homogenous mixture. Proniosomal 
gel viscosity was determined by Brookfield Viscometer at 0.5, 1, 2, 3, 4, 
5, 10, 20, 30, 40, 50, and 100 with increasing and decreasing rpm [6].
Rate of spontaneity
Rate of spontaneity is calculated by counting the number of niosomes 
formed after hydration of proniosomes for 15–20 min.. Approximately 
10 or 20 mg of proniosomal gel is transferred to a glass bottle and 
spread uniformly around walls [7]. 2 ml of saline solution (0.154M 
NaCl) was added along the walls and left aside for 20 min. Then, a drop 
was withdrawn and placed on Neubauer chamber to count the number 
of vesicles. The number of niosomes eluted from proniosomes was 
counted [7].
Scanning electron microscopy (SEM)
The surface morphology and size distribution of proniosomes were 
perceived by SEM. A double-sided tape was affixed on the aluminum 
stubs, and the proniosomal powder was evenly spread over it. The 
aluminum stub was further kept in a vacuum chamber of SEM [8].
Thermal analysis
Differential scanning calorimetry (DSC) analysis was studied to 
determine the physical state of the drug within the gel and also, to 
determine the possible interactions between drug and the vesicle 
ingredients. For this, 6 mg of each sample (drug, Span 20, drug-free, and 
drug-loaded proniosomes) was sealed in a standard aluminum pan and 
subjected to analysis using DSC-4000 (PerkinElmer, USA). The samples 
were scanned at a heating rate of 10°C/min. An empty pan was used as 
a reference. The thermograms were obtained in the temperature range 
of 40–350°C [9,10].
Drug entrapment efficiency
Proniosomal gel (100 mg) was distributed in brine solution and 
warmed slightly for the formation of niosomes. Then, the solution was 
centrifuged at 18,000 rpm for 40 min at 37°C. The subsequent solution 
was filtered and examined spectrophotometrically at 281 nm and 
247 nm for ethinylestradiol and levonorgestrel against 30% v/v PEG 
200 [11,12].















In vitro release studies of proniosomal gel were performed using 
Keshary-Chien cell permeation system. Cellophane membrane was 
settled in between the half-cell of Keshary permeation cell [13,14]. 
Donor half-cell containing proniosomal gel formulation with 10 mg 
drug was adhered to the outer side of the membrane, and the receptor 
half-cell had a solution containing 30% v/v PEG in saline solution 
to maintain the sink condition. The receptor compartment was 
surrounded by a water bath for maintaining the temperature 37±2° for 
24 h. The top of the donor compartment was 10 ml, and the area of 
donor compartment was 1.31 cm. At the 45 min of the time interval, 
5 ml sample was taken from the receptor compartment and the same 
volume of 30% v/v PEG saline solution was added in it. Samples 
collected were analyzed ultraviolet (UV) spectrophotometrically for 
ethinylestradiol at 281 nm and for levonorgestrel against the respective 
blank solution.
Stability studies
Stability studies were determined by means of keeping the proniosomal 
gel at three different temperatures, that is, refrigerator temperature 
at 4–6°C, room temperature at 37±20°C, and in the oven at 45±20°C. 
Throughout the study, proniosomal formulations have been stored in 
aluminum foil-sealed glass vials. The temperature glass vials containing 
formulation are fully protected with aluminum foil [15-17].
RESULTS AND DISCUSSION
The formulation variables greatly influence the characteristics as well 
as the performance of the obtained formulation. The proniosomal 
formulations were optimized by “factor at one time.” First, a different 
grade of the commonly used surfactants, that is, spans or tweens was 
screened to choose the suitable surfactant for the formulations. The 
amount of the selected surfactant was varied thus at high and low levels. 
Similarly, the amount of the lecithin and the cholesterol was also varied 
to high levels to study their influence on the formulation characteristics. 
Finally, the drug amount was optimized. Tweens and spans are the 
popular non-ionic surfactants used as vesicle-forming agent in the 
preparation of niosomes and proniosomes. On evaluating different 
grades of spans, for example, 20, 40, 60, or 80 and tweens, for example, 
20, 60, or 80, it was found that their nature considerably affected the 
drug entrapment and the final vesicle size. Percentage entrapment 
efficiency of the proniosomes was found to be higher with spans than 
with tweens which might be attributed to the high hydrophobicity of 
spans than tweens. Spans also have low hydrophile-lipophile balance 
Table 1: Composition of proniosomal gel formulations
S. No Drug (mg) Surfactant  (span 20) (mg) Soya lecithin (mg) Cholesterol  (mg) Alcohol (ml)
F1 10 50 100 100 0.5
F2 10 50 150 100 0.5
F3 10 100 100 - 0.5
F4 10 100 - 100 0.5
F5 10 50 100 150 0.5
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value and higher phase transition temperature (Tc); thus, greater 
amount of the drug was expected to be encapsulated in the lipid layers 
of the vesicles. Higher phase transition temperature (Tc) further aids in 
the formation of ordered gel with less leaky lipid bilayers.
The amount of the selected surfactant “span 20” was further 
varied at low level (50 mg) and high level (100 mg). The surfactant 
concentration was found to be an important variable in the formation 
of niosomal vesicles and encapsulation of drug therein. The variation 
in the concentration greatly affected the entrapment efficiency with a 
predominant effect on vesicle size also. Lecithin acts as cosurfactant in 
the formation of smaller size proniosomal vesicles and also improves 
the drug permeation into vesicles by increasing hydrophobicity. The 
non-hydrogenated lecithin used in this study allowed the chains to 
bend, loosening the adjacent molecule that assembled to form the 
niosomal membrane. The loosely packed membrane was thus formed 
which showed high permeability. The concentration of cholesterol 
also plays an important role in the formation and drug entrapment in 
the vesicles, due to these, molecules house themselves as “vesicular 
cement” into the bilayers of the surfactant membranes. This 
mechanism is responsible for the permeability, rigidity, and stability 
of the niosomal vesicles.
Investigation of physicochemical compatibility of drug and polymer
DSC analysis
No major peak of drug  is observed in drug loaded formulation and 
no major difference was observed in the drug-free and drug-loaded 
proniosomes. The endothermic peak of the niosomal bilayer was 
changed from 84.88°C to a broad wide peak at 90.64°C after drug 
loading due to some cholesterol molecules (Fig. 1). DSC thermogram 
of proniosome (D) with drug (C), blank proniosomes (B), span 20 (A). 
It indicates that there is integration between the span 20 molecules, 
cholesterol and soya lecithin and also indicates the amorphous nature 
of the drug since no peak is observed in the drug-loaded proniosome 
formulation.
Physicochemical characterization of patches
The study of organoleptic properties of the proniosomal gel formulations 
F1–F5 is presented in Table 2. Soya lecithin gave a yellowish colour to 
the formulation F1, F2, F4 and F5. F2 shows the best spreadability and 
homogeneity among the five formulations. Color of formulations F1, F2, 
F4, and F5 was found out to be yellowish-white, and F3 showed white 
color due to the absence of soya lecithin (Table 2). Homogeneity of F1 
is best in all of the formulation; spreadability of F1, F2, and F5 showed 
excellent spreadability in all formulations (Table 2). There was no oily 
feel in any of the formulations. Proniosomal gel was also analyzed by an 
optical microscope at ×40 to represent coloration and physical phase 
of gel. Optical microscopy revealed that niosomes have been round and 
homogenous. The proniosomes were found to have a sweet fragrance 
and were tasteless.
Vesicle size analysis
Niosomes formed from the formulation of proniosomes have vesicle 
size very similar to each other. Gel containing formulation F2 produces 
the smallest vesicular sized niosomes (Table 3).
Viscosity study
Viscosity was determined at different rpm. Proniosomal gel 
formulations were studied for physical characteristics viscosity using 
Brookfield Viscometer (Table 3).
Rate of spontaneity
Rate of spontaneity was determined from the prepared formulation of 
proniosomal gel; the prepared formulation result is shown in Table 3, 
that is, prepared with span 20. The rate of hydration of all formulations 
was not significantly distinctive (Table 3).
Drug entrapment efficiency
Among all formulations, Span 20 has shown the highest encapsulation 
efficiency and mixed formulation with Span 20 showed least encapsulation 
efficiency (Table 3).
Fig. 1: Differential scanning calorimetry thermogram report
Table 2: Organoleptic controls* at the end of 24 h
Control F1 F2 F3 F4 F5
Ease of absorption ++ ++ ++ ++ ++
Spreadability +++ +++ ++ ++ +++
Oily feel − − − − −
Homogeneity +++ ++ + ++ ++
Stickiness +++ ++ ++ +++ ++
Water dilution ++ ++ ++ ++ ++
Odor + + + + +
Color YW YW W YW YW
−: Unavailable, +: Moderate, ++: Good, +++: Best, W: White, YW: Yellowish-white, 
*mean±SD, n=3. SD: Standard deviation
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SEM
SEM images of optimized proniosomal gel, Span 20 formulations, size 
distribution, and morphology of proniosomes were determined by SEM as 
shown in Fig. 2, proniosomal gel formulations were examined, and images 
purely indicate spherical-shaped particles with a size range of 46.4 nm, 
62.4 nm, 72.8 nm, and 80.2 nm. The morphology of the niosomes formed 
on hydration of proniosomal formulations and the effect of the amount of 
cholesterol in vesicle formation were also evaluated using SEM.
In vitro drug release
In vitro drug release was carried out by using domestically fabricated 
Keshary Chien diffusion cell through cellophane membrane. It was 
apparent that the incorporation of a drug into vesicular systems 
resulted in sustaining the drug release profile for a longer period of time. 
Ethinylestradiol and levonorgestrel were released from the proniosomes 
with an initial fast release phase followed by a sustained release pattern. 
The initial fast release was due to desorption of the drug molecules that 
were present on the surface of formed niosomes. In the later phase, the 
ethinylestradiol and levonorgestrel release was regulated by diffusion 
through the inflated bilayers and exhibited sustained release pattern. 
The percentage cumulative release in 24 h was found ranging in 74–
86%, and F2 system has shown the maximum percentage of release 
in 24 h as shown in Table 4. The optimized proniosomes (F2) showed 
a significant sustained drug release which was 86.42% after 24 h. The 
formulation prepared with high cholesterol content (familial combined 
hyperlipidemia) showed a more sustained release of ethinylestradiol 
and levonorgestrel with reduced initial burst release effect. Because the 
high cholesterol content facilitated the formation of compact niosomal 
bilayers which further reduced permeability and thus, hindered the 
release of drug entrapped.. When the release data were fitted into various 
kinetic models, it was found that ethinylestradiol and levonorgestrel 
release from the proniosomal formulations followed Higuchi kinetics. 
This model suggested the diffusion controlled release of the drug.
Stability study
Stability was scrutinized to determine the fraction of drug entrapped 
inside the vesicles of proniosomal formulation at temperature 4–6°C, 
37°C, and 45±2°C for 48 days. Based on the results of vesicular size, 
Percentage drug content and Percentage entrapment efficiency (Table 
5). From the result of the stability study test, it showed that the 
proniosomal formulations were highly stable at room temperature as 
well as refrigeration temperature.
As evident from the results, ethinylestradiol and levonorgestrel leakage 
from the vesicles may be due to the phase transition of the surfactant 
and lipid at 37°C (Table 5). However, no significant change was observed 
in the vesicular size or percentage entrapment of the formulations 
when stored at 4–8°C and 45±2°C for the period of 90 days.
CONCLUSIONS
The results of the study indicated that ethinylestradiol and levonorgestrel 
proniosomal gel containing lecithin, cholesterol, and in combination 
of surfactant Span 20 formulations was prepared successfully using 
coacervation-phase separation method. F2 formulation showed highest 
Table 3: Physicochemical evaluation of proniosomal gel formulation
Formulation code Viscosity study* Vesicle size (nm)* Spontaneity* (niosome/mm3) Percentage of drug entrapment*
F1 16 395.2 (9.687±0.883)×103 80.42±0.61
F2 15 385.4 (9.563±0.578)×103 86.85±0.85
F3 13 315.6 (5.477±0.315)×103 78.71±0.42
F4 15 365.6 (6.687±0.695)×103 79.25±0.66
F5 16 340.6 (6.681±0.752)×103 81.12±0.96
*Mean, n=3
Table 4: Cumulative percentage drug release*
Time (h) F1 F2 F3 F4 F5
0.5 4.75±0.34 5.29± 1.08 3.65±0.867 0.4.04±0.35 4.51±1.3
1 7.94±0.34 8.76±1.76 6.3±0.34 5.08±1.36 5.23±0.42
2 10.23±1.23 11.89±0.54 9.21±0.28 0.10.16±1.75 9.78.15±0.08
3 15.86±0.91 17.21±1.37 14.29±1.73 16.24±0.45 16.15±0.98
4 21.23±0.14 22.78±1.41 21.76±1.87 20.69±0.78 21.87±1.98
6 34.67±0.56 36.98±1.43 33.72±1.54 34.03±1.3 33.89±0.65
12 56.23±1.47 58.91±1.79 56.98±1.46 55.27±1.62 55.38±1.48
24 80.42±0.67 86.42±0.61 76.08±9.98 74.85±0.56 80.51±0.67
*Mean±SD, n=3. SD: Standard deviation
Table 5: Stability study analysis**
Characteristics Before storage After 3 months’ storage
4–8°C 37±2°C 45±2°C
Vesicle size (nm) 288.2 375.2 385.2 185.2
Percentage entrapment 77.95±0.12 80.42±0.08 85.05±0.85 63.85±0.69
Percentage drug content 79.27±0.04 83.76±0.23 86.03±0.61 75.12±0.35
**Mean±SD, n=3. SD: Standard deviation
Fig. 2: Scanning electron micrograph of proniosomes
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entrapment efficiency. Proniosomal gel formulations were evaluated 
for the entrapment efficiency, UV spectroscopy, viscosity, vesicle size 
and shape with SEM, and optical microscopy, and the results were 
found in the acceptable range. The absence of cholesterol content 
in formulations F4 was found to cause low percentage entrapment 
efficiency (78.1%) which might be due to leakage of the vesicles. Further, 
cholesterol absence reduces vesicles size of the formulation. F4 showed 
the lowest drug release (74.85%) because soya lecithin is absent in the 
formulation. F3 showed the lowest drug release (74.85%) because soya 
lecithin is absent in the formulation. Increased level of soya lecithin in 
F1 and F2 showed high drug release (80.42% and 86.01%, respectively). 
F4 showed the higher drug entrapment efficiency due to higher level 
of cholesterol. In vitro dissolution studies showed satisfactory results, 
and the permeation studies showed good control release for prolonged 
period of time. Permeation studies showed the highest permeation 
of proniosomal gel formulation F2, and in vitro rat skin permeation 
studies proved that good amount of drug is permeated and has good 
stability characteristics. The study showed that the proniosomal gel 
formulation was quite stable at refrigeration and room temperature 
as well. All the results suggest that ethinylestradiol and levonorgestrel 
drug proniosomal gel formulations may be used as an antifertility 
treatment and can be further subjected to clinical trials to find out the 
adverse effects [18]. The high stability of the system further favors the 
potential of proniosomes for systemic delivery of therapeutics.
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